Latest News about XLRN
Recent news which mentions XLRN
3 Dow Stocks to Take Seriously in 2023
November 29, 2022
From InvestorPlace
Is Merck Stock a Buy?
November 20, 2021
From Motley Fool
Merck Is a Dividend Play Ready to Get Back in Gear
November 16, 2021
From InvestorPlace
Is Merck's Planned Acquisition of Acceleron in Trouble?
November 12, 2021
From Motley Fool
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
From Benzinga
3 Dow Stocks That Are Screaming Buys in November
November 09, 2021
From Motley Fool
3 Best Biotech Stocks to Buy in November
November 08, 2021
From Motley Fool
Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move?
November 06, 2021
From Motley Fool
Merck Pushes Acceleron Buyout By Refiling For Antitrust Review
November 01, 2021
From Benzinga
From Motley Fool
2 Biotech Stocks That Could Go Parabolic This Week
October 24, 2021
From Motley Fool
Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg
October 21, 2021
From Benzinga
2 Best Biotech Stocks to Buy Right Now
October 18, 2021
From Motley Fool
2 Top Healthcare Stocks That Could Be Bought Out in 2022
October 16, 2021
From Motley Fool
Better COVID-19 Stock: Merck or Pfizer?
October 16, 2021
From Motley Fool
3 Top Warren Buffett Stocks to Buy in October
October 10, 2021
From Motley Fool
3 Reasons to Buy Merck Stock Right Now
October 09, 2021
From Motley Fool
Is an Acquisition of Acceleron a Smart Move for Merck?
October 08, 2021
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
October 07, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2021
October 04, 2021
From Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
October 03, 2021
From Benzinga
Activist Investor Thinks Merck Undervalues Acceleron Buy
October 01, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021
October 01, 2021
From Benzinga
10 Biggest Price Target Changes For Friday
October 01, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
From Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
From Benzinga
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
September 30, 2021
From Benzinga